Ivabradine Hydrochloride
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Ivabradine Hydrochloride
- Ivabradine Hydrochloride: Repurposing Evaluation — Insufficient Data to Proceed
Ivabradine Hydrochloride: Repurposing Evaluation — Insufficient Data to Proceed
One-Sentence Summary
Ivabradine hydrochloride is a selective If (funny current) inhibitor with established cardiovascular applications in heart rate reduction. The TxGNN model has not generated any repurposing predictions for this compound in the current Evidence Pack, and critical data gaps — including missing DrugBank ID, mechanism of action, and regulatory records — prevent a complete evaluation from being conducted.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no clinical evidence; no predictions available) |
| Taiwan Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why No Prediction is Available
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on the drug name alone, ivabradine hydrochloride is known to be a selective inhibitor of the sinoatrial node If channel, reducing heart rate without affecting myocardial contractility — a mechanism relevant to cardiovascular conditions. However, because no DrugBank ID was resolved and predicted_indications is empty, the TxGNN model could not produce repurposing candidates for this compound.
Without predicted indications, there is no repurposing hypothesis to evaluate, and no mechanistic link to a new indication can be reasonably assessed at this stage.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for ivabradine hydrochloride contains multiple blocking data gaps — no DrugBank ID, no MOA, no TFDA regulatory records, and most critically, no TxGNN-predicted repurposing candidates. Without a predicted indication, this report cannot fulfill its primary purpose.
To proceed, the following is needed:
- Resolve DrugBank ID for ivabradine (or ivabradine hydrochloride as salt form) to enable TxGNN model input
- Re-run TxGNN prediction pipeline once DrugBank ID is confirmed
- Retrieve mechanism of action data from DrugBank API
- Download and parse TFDA package insert (仿單 PDF) to populate safety warnings and contraindications
- Confirm original approved indications from the regulatory source to establish baseline context
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.